Linctus Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 31-05-2024
- Paid Up Capital ₹ 0.10 M
as on 31-05-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.65 M
as on 31-05-2024
- Revenue 3404.00%
(FY 2017)
- Profit 199.67%
(FY 2017)
- Ebitda 98.59%
(FY 2017)
- Net Worth 1.78%
(FY 2017)
- Total Assets 95.07%
(FY 2017)
About Linctus Pharma
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.65 M.
Pawan Jha, Khusboo Kumari, Ranjan Kumar, and One other member serve as directors at the Company.
- CIN/LLPIN
U51397JH2014PTC002333
- Company No.
002333
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Aug 2014
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Jharkhand
Industry
Company Details
- Location
Ranchi, Jharkhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Linctus Pharma Private Limited offer?
Linctus Pharma Private Limited offers a wide range of products and services, including Vitamins & Supplements, Mineral Supplements.
Who are the key members and board of directors at Linctus Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pawan Jha  | Managing Director | 18-Jun-2015 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Khusboo Kumari | Director | 25-Aug-2014 | Current |
| Ranjan Kumar | Director | 25-Aug-2014 | Current |
| Sumit Mittal | Director | 18-Jun-2015 | Current |
Financial Performance of Linctus Pharma.
Linctus Pharma Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 3404% increase. The company also saw a substantial improvement in profitability, with a 199.67% increase in profit. The company's net worth moved up by a moderate rise of 1.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Linctus Pharma?
In 2017, Linctus Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 27 May 2020 | ₹0.15 M | Open |
Canara Bank Creation Date: 18 Mar 2020 | ₹1.50 M | Open |
How Many Employees Work at Linctus Pharma?
Unlock and access historical data on people associated with Linctus Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Linctus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Linctus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
